Combination Chemotherapy Followed by Surgery in Treating Patients With Stomach Cancer

NYU Langone Health

Overview

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and combining chemotherapy with surgery may kill more tumor cells. PURPOSE: This phase II trial is studying how well irinotecan and cisplatin followed by surgery, floxuridine, and cisplatin work in treating patients with stomach cancer.

OBJECTIVES: * Determine the complete and partial response rates and time to treatment failure in patients with advanced gastric cancer treated with neoadjuvant irinotecan and cisplatin followed by surgery then intraperitoneal floxuridine and cisplatin. * Determine the rate of potentially curative surgery in patients receiving this regimen. * Determine the toxicity and tolerance of this regimen in these patients. OUTLINE: Patients receive cisplatin IV and irinotecan IV once a week for 4 weeks. This course is repeated 2 weeks later. Patients who achieve complete or partial remission or stable disease undergo resection 4 weeks after the last chemotherapy dose. Patients with no residual macroscopic disease begin adjuvant intraperitoneal (IP) chemotherapy 1 week after surgery. Chemotherapy consists of floxuridine IP over 30 minutes on days 1-3 and days 22-24 and cisplatin IP on days 3 and 24. PROJECTED ACCRUAL: A total of 18-33 patients will be accrued for this study within 2 years.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Conditions

Gastric Cancer

Interventions

cisplatinDRUG

floxuridineDRUG

irinotecan hydrochlorideDRUG

adjuvant therapyPROCEDURE

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

DISEASE CHARACTERISTICS: * Histologically proven, previously untreated gastric cancer * Stage IB, II, III, or IV (T3-4, N0 OR any T, N1-2, M0) * No metastases PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * SWOG 0-2 Life expectancy: * Not specified Hematopoietic: * WBC at least 4000/mm\^3 * Platelet count at least 100,000/mm\^3 * Hemoglobin at least 9 g/dL Hepatic: * Bilirubin less than 2 mg/dL * SGOT/SGPT no greater than 2 times upper limit of normal (ULN) * Alkaline phosphatase no greater than 3 times ULN * PT, aPTT, and TT normal * No Gilbert's disease Renal: * BUN no greater than 30 mg/dL * Creatinine no greater than 1.5 mg/dL OR * Creatinine clearance greater than 60 mL/min Cardiovascular: * No myocardial infarction within the past 3 months * No congestive heart failure requiring therapy Other: * No other invasive malignancy in the past 5 years except adequately treated basal or squamous cell skin cancer or carcinoma in situ of the cervix * No active or uncontrolled infection * HIV negative * No other severe concurrent disease * No psychiatric disorders that would preclude compliance * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No prior chemotherapy for gastric cancer Endocrine therapy: * Not specified Radiotherapy: * No prior radiotherapy for gastric cancer Surgery: * No prior surgery for gastric cancer * No emergent need for surgery for gastrointestinal obstruction, perforation, or hemorrhage

Locations (1)

NYU Cancer Institute at New York University Medical Center

New York, New York, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.